FDA publishes new guidance to promote innovation in general wellness and clinical decision support, impacting medical AI including radiology.
Key Details
- 1FDA released updated guidance for general wellness products and clinical decision support (CDS) software.
- 2New guidelines aim to reduce regulatory confusion and encourage rapid AI innovation in healthcare devices.
- 3Commissioner Makary said FDA wants to 'promote more innovation with AI and medical devices.'
- 4Hospital OSF HealthCare developed 'CliniPane,' an in-house AI platform for care team notification based on patient deterioration.
- 5Anthropic launched Claude for Healthcare, a HIPAA-compliant medical LLM, challenging ChatGPT.
- 6Radiology-specific mention: Aidoc named a former AMA president as chief medical officer.
Why It Matters
Clearer regulatory direction for AI-driven CDS products, including radiology tools, may accelerate deployment, reduce compliance worries, and foster innovation. Hospital in-house AI and new medical LLM entrants signal potent competition and rapid evolution in imaging and clinical AI.
Source
HealthExec
Related News
•AuntMinnie
Vast Majority of FDA-Cleared Radiology AI Devices Lack Outcome Trials
Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
•Radiology Business
Radiology Partners Urges FDA for Clarity on Imaging AI Regulations
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
•Radiology Business
FDA Solicits Public Input on Regulating Generative AI in Medical Devices
The FDA is seeking public feedback on how to regulate generative AI in medical devices, recognizing both its promise and risks.